Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
12:33pm, Tuesday, 04'th Nov 2025
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It
12:11pm, Tuesday, 04'th Nov 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin
Sarepta Therapeutics Stock Tumbles After Trial Data
11:11am, Tuesday, 04'th Nov 2025
Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say
10:30am, Tuesday, 04'th Nov 2025
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key
Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.
06:20am, Tuesday, 04'th Nov 2025
The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript
05:36am, Tuesday, 04'th Nov 2025
Sarepta Therapeutics, Inc. ( SRPT ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research
Sarepta slumps as gene therapy setback adds to drug pipeline woes
04:27am, Tuesday, 04'th Nov 2025
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pip
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates
11:58pm, Monday, 03'rd Nov 2025
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.62 per share a year ago.
Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success
06:26pm, Monday, 03'rd Nov 2025
Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.
Sarepta's Duchenne gene therapy misses main goal in study
04:24pm, Monday, 03'rd Nov 2025
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
04:05pm, Monday, 27'th Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasd
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
06:46am, Thursday, 23'rd Oct 2025
Funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline
11:49am, Friday, 10'th Oct 2025
Sarepta Therapeutics is showing signs of recovery, driven by its robust pipeline and recent revenue growth, despite past clinical setbacks. SRPT's near-term catalyst is SRP-9003, a gene therapy for Li
What's Going On Sarepta Stock On Wednesday?
11:19am, Wednesday, 08'th Oct 2025
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.
